A federal advisory committee voted Thursday to open up rules on seven peptides, including BPC-157 and TB-500. The vote was close. It is non-binding. The FDA has given no signal on whether it will move in step with the panel. The move came after weeks of community hearings. Wellness backers lobbied intensely for wider access. RFK Jr. was among them. Critics say these compounds have no solid safety track record or help for most uses. The call could change how the agency handles a part of the wellness market that is surging ahead. Market observers are watching to see if the agency adopts the plan. A spokesperson for the regulator offered no firm timeline for a response. Critics argue the change would open up access to products that users favor. Health groups warn that looser rules could invite misuse across a quickly growing market. The advisory vote only clears a path to a change, and the ultimate call rests with the FDA.